Literature DB >> 19383358

A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Pavel Gromov1, Julio E Celis, Irina Gromova, Fritz Rank, Vera Timmermans-Wielenga, José M A Moreira.   

Abstract

Cancer, being a major healthcare concern worldwide, is one of the main targets for the application of emerging proteomic technologies and these tools promise to revolutionize the way cancer will be diagnosed and treated in the near future. Today, as a result of the unprecedented advances that have taken place in molecular biology, cell biology and genomics there is a pressing need to accelerate the translation of basic discoveries into clinical applications. This need, compounded by mounting evidence that cellular model systems are unable to fully recapitulate all biological aspects of human dissease, is driving scientists to increasingly use clinically relevant samples for biomarker and target discovery. Tissues are heterogeneous and as a result optimization of sample preparation is critical for generating accurate, representative, and highly reproducible quantitative data. Although a large number of protocols for preparation of tissue lysates has been published, so far no single recipe is able to provide a "one-size fits all" solubilization procedure that can be used to analyse the same lysate using different proteomics technologies. Here we present evidence showing that cell lysis buffer 1 (CLB1), a lysis solution commercialized by Zeptosens [a division of Bayer (Schweiz) AG], provides excellent sample solubilization and very high 2D PAGE protein resolution both when using carrier ampholytes and immobilized pH gradient strips. Moreover, this buffer can also be used for array-based proteomics (reverse-phase lysate arrays or direct antibody arrays), allowing the direct comparison of qualitative and quantitative data yielded by these technologies when applied to the same samples. The usefulness of the CLB1 solution for gel-based proteomics was further established by 2D PAGE analysis of a number of technically demanding specimens such as breast carcinoma core needle biopsies and problematic tissues such as brain cortex, cerebellum, skeletal muscle, kidney cortex and tongue. This solution when combined with a specific sample preparation technique - cryostat sectioning of frozen specimens - simplifies tissue sample preparation and solves most of the difficulties associated with the integration of data generated by different proteomic technologies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19383358      PMCID: PMC5527781          DOI: 10.1016/j.molonc.2008.09.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  51 in total

Review 1.  Proteomics in translational cancer research: toward an integrated approach.

Authors:  Julio E Celis; Pavel Gromov
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

Review 2.  Current two-dimensional electrophoresis technology for proteomics.

Authors:  Angelika Görg; Walter Weiss; Michael J Dunn
Journal:  Proteomics       Date:  2004-12       Impact factor: 3.984

Review 3.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

4.  The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

Authors:  Amy Rapkiewicz; Virginia Espina; Jo Anne Zujewski; Peter F Lebowitz; Armando Filie; Julia Wulfkuhle; Kevin Camphausen; Emanuel F Petricoin; Lance A Liotta; Andrea Abati
Journal:  Cancer       Date:  2007-06-25       Impact factor: 6.860

Review 5.  The biological impact of mass-spectrometry-based proteomics.

Authors:  Benjamin F Cravatt; Gabriel M Simon; John R Yates
Journal:  Nature       Date:  2007-12-13       Impact factor: 49.962

6.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

Review 7.  Modeling of protein signaling networks in clinical proteomics.

Authors:  D H Geho; E F Petricoin; L A Liotta; R P Araujo
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2005

8.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays.

Authors:  Julia D Wulfkuhle; Joy A Aquino; Valerie S Calvert; David A Fishman; George Coukos; Lance A Liotta; Emanuel F Petricoin
Journal:  Proteomics       Date:  2003-11       Impact factor: 3.984

9.  Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.

Authors:  Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezón; Pavel Gromov; Tao Shen; Vera Timmermans; Fritz Rank
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

Review 10.  Human protein atlas and the use of microarray technologies.

Authors:  S Hober; M Uhlén
Journal:  Curr Opin Biotechnol       Date:  2008-01-09       Impact factor: 9.740

View more
  13 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

Review 2.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

3.  A mechanical cell disruption microfluidic platform based on an on-chip micropump.

Authors:  Yinuo Cheng; Yue Wang; Zhiyuan Wang; Liang Huang; Mingzhao Bi; Wenxiao Xu; Wenhui Wang; Xiongying Ye
Journal:  Biomicrofluidics       Date:  2017-04-04       Impact factor: 2.800

4.  Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Authors:  Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2009-11-23       Impact factor: 6.603

5.  A single lysis solution for the analysis of tissue samples by different proteomic technologies.

Authors:  Pavel Gromov; Julio E Celis; Irina Gromova; Fritz Rank; Vera Timmermans-Wielenga; José M A Moreira
Journal:  Mol Oncol       Date:  2008-10-02       Impact factor: 6.603

6.  Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.

Authors:  Julio E Celis; Teresa Cabezón; José M A Moreira; Pavel Gromov; Irina Gromova; Vera Timmermans-Wielenga; Takuji Iwase; Futoshi Akiyama; Naoko Honma; Fritz Rank
Journal:  Mol Oncol       Date:  2009-02-03       Impact factor: 6.603

7.  Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Authors:  Teresa Cabezón; Irina Gromova; Pavel Gromov; Reza Serizawa; Vera Timmermans Wielenga; Niels Kroman; Julio E Celis; José M A Moreira
Journal:  Mol Cell Proteomics       Date:  2012-11-20       Impact factor: 5.911

8.  Single-cell chemical lysis on microfluidic chips with arrays of microwells.

Authors:  Chun-Ping Jen; Ju-Hsiu Hsiao; Nikolay A Maslov
Journal:  Sensors (Basel)       Date:  2011-12-30       Impact factor: 3.576

Review 9.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Authors:  Kristy J Gotink; Henk M W Verheul
Journal:  Angiogenesis       Date:  2009-12-11       Impact factor: 9.596

10.  Single-cell electric lysis on an electroosmotic-driven microfluidic chip with arrays of microwells.

Authors:  Chun-Ping Jen; Tamara G Amstislavskaya; Ya-Hui Liu; Ju-Hsiu Hsiao; Yu-Hung Chen
Journal:  Sensors (Basel)       Date:  2012-05-25       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.